摘要
目的评价治疗非小细胞肺癌(NSCLC)常用的3种化疗方案的临床疗效和成本-效果。方法用药物流行病学的回溯法,将在本院住院的46例采用吉西他滨、多西他赛和长春瑞滨联合顺铂化疗的NSCLC患者,分成3组:(1)GP组24例,给予吉西他滨1 200 mg.m-2静脉滴注,d 1和d 8,顺铂60 mg.m-2静脉滴注,d 1;(2)DP组10例,给予多西他赛75 mg.m-2静脉滴注,d 1,顺铂60 mg.m-2静脉滴注,d 1;(3)VP组12例,给予长春瑞滨25 mg.m-2静脉滴注,d 1和d 8,顺铂60 mg.m-2静脉滴注,d 1。均治疗2个周期。运用药物经济学的成本-效果分析法进行研究。结果 GP、DP和VP 3组的有效率分别为38%、40%和42%(P>0.05),成本-效果比(C/E)分别为284.2、162.8和138.1;GP、DP组相对VP组的增量成本-效果比(△C/△E)分别为-1198.64、-142.5。结论 VP方案是3种方案中最经济的治疗方案。
AIM To evaluate the cost-effectiveness of three chemotherapy protocols in non-small cell lung cancer（NSCLC）for the purpose of lower cost,higher quality medical care.METHODS A retrospective study was conducted on the records of 46 patients who were under the chemotherapies of gemcitabine,docetaxel,and vinorelbine for the treatment of NSCLC in the department of respiratory medicine of our hospital from January through October in 2008.There were three treatment protocols,gemcitabine ＋ cisplatin（GP,n = 24）,docetaxel ＋ cisplatin（DP,n = 10）,and vinorelbine ＋ cisplatin（VP,n = 12）.An incremental cost-effectiveness ratio（ICER）was used to assess the cost-effectiveness for each intervention.RESULTS The effective rate of GP,DP and VP were 38%,40% and 42%（P 0.05）,respectively.The cost-effectiveness ratio（C/E）of GP,DP and VP were 284.2,162.8 and 138.1,respectively.Comparing with VP,ICER（△C/△E）of GP and DP were-1 198.64 and-142.5.CONCLUSION VP has a better cost-effectiveness and is more economic than GP and DP.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2010年第12期942-945,共4页
Chinese Journal of New Drugs and Clinical Remedies
关键词
癌
非小细胞肺
经济学
药学
费用效益分析
抗肿瘤联合化疗方案
吉西他滨
多西他赛
长春瑞滨
顺铂
carcinoma
non-small-cell lung
economics
pharmaceutical
cost-benefit analysis
antineoplastic combined chemotherapy protocols
gemcitabine
docetaxel
vinorelbine
cisplatin
